EQS Group-News: Zur Rose Group AG / Key word(s): AGMEGM
Extraordinary General Meeting of Shareholders
The shareholders of Zur Rose Group AG at today's Extraordinary General Meeting of Shareholders approved the Board of Directors' proposal to increase the company's share capital from CHF 35,761,820.25 by up to CHF 15,326,487.00 to up to CHF 51,088,307.25 by issuing up to 2,665,476 new registered shares with a nominal value of CHF 5.75 per share. The Zur Rose Group is seeking to generate net proceeds of approximately CHF 200 million from the capital increase with rights issue. Details of the rights issue were announced by the Group this morning. The capital increase will serve to fund the acquisition of medpex and further organic growth initiatives.
Investors and analyst contact
Zur Rose Group
The Swiss Zur Rose Group is Europe's largest online pharmacy and one of the leading medical wholesalers in Switzerland. With its business model, it offers high-quality, safe and cost-effective pharmaceutical care and thus contributes to reducing healthcare costs. It is also characterized by the continuous further development of digital services in the field of drug management in order to increase therapy safety. The creation of added value and a pronounced patient orientation make the Group an important strategic partner for service providers, cost units and industry.
The Zur Rose Group is internationally present with strong brands, including Germany's best-known pharmacy brand DocMorris. The company employs over 1,000 people at various locations and generated a turnover of CHF 983 million in the 2017 financial year. The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). The CHF 115 million corporate bond issued in July 2018 is also listed on the SIX Swiss Exchange (securities number 42146044, ISIN CH0421460442, ticker ZRO18). Further information at zurrosegroup.com
|Company:||Zur Rose Group AG|
|Phone:||+41 52 724 08 14|
|Listed:||SIX Swiss Exchange|
|End of News||EQS Group News Service|